echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Novavax's COVID-19 vaccine is "very effective" against UK variants

    Novavax's COVID-19 vaccine is "very effective" against UK variants

    • Last Update: 2021-03-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Novavax announced in its UK- based Phase III trial that its COVID-19 vaccine NVX-CoV2373 is 96.
    3% effective in protecting mild, moderate and severe diseases caused by the original COVID-19 strain.

    COVID-19

    This study recruited more than 15,000 18-84-year-old subjects, of which 27% were older than 65 years old.
    In addition to the final efficacy analysis of the original COVID-19 strain, Novavax also found that NVX-CoV2373 is 86.
    3% effective against the B.
    1.
    1.
    7 mutant first discovered in the UK.
    According to Novavax's data, this shows that the overall efficacy of the vaccine is 89.
    7%.

    In addition to the final efficacy analysis of the original COVID-19 strain, Novavax also found that NVX-CoV2373 is 86.
    3% effective against the B.
    1.
    1.
    7 mutant first discovered in the UK.
    In addition to the final efficacy analysis of the original COVID-19 strain, Novavax also found that NVX-CoV2373 is 86.
    3% effective against the B.
    1.
    1.
    7 mutant first discovered in the UK.

    In addition to the data of the third phase, Novavax also announced the data of the Phase IIb trial of NVX-CoV2373 in South Africa.
    In regions where most COVID-19 cases are attributed to the B.
    1.
    351 mutant circulating in South Africa, the efficacy of NVX-CoV2372 is 55.
    4%.

    Stanley Erck, President and CEO of Novavax, said: "The data show that NVX-CoV2373 provides complete protection against the most serious diseases.
    Importantly, both studies have confirmed the efficacy against mutant viruses.
    March 11th is the World Health Organization.
    The first anniversary of the COVID-19 pandemic was officially announced.
    With these data, we are more motivated to promote the COVID-19 vaccine NVX-CoV2373 to serve more people.

     

    Original source:

    Original source:

    http:// href="http://" target="_blank" rel="noopener">http:// style="vertical-align: inherit;"> http://

    Leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.